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Abstract 
Motivation: Ebola viruses are not pathogenic but can be adapted to replicate and cause disease in 
rodents. Here, we used a structural bioinformatics approach to analyze the mutations associated with 
Ebola virus adaptation to rodents to elucidate the determinants of host-specific Ebola virus pathogenic-
ity. 
Results: We identified 33 different mutations associated with Ebola virus adaptation to rodents in the 
proteins GP, NP, L, VP24, and VP35. Only VP24, GP and NP were consistently found mutated in 
rodent-adapted Ebola virus strains. Fewer than five mutations in these genes seem to be required for 
the adaptation of Ebola viruses to a new species. The role of mutations in GP and NP is not clear. 
However, three VP24 mutations located in the protein interface with karyopherin a5 may enable VP24 
to inhibit karyopherins and subsequently the host interferon response. Three further VP24 mutations 
change hydrogen bonding or cause conformational changes. Hence, there is evidence that few muta-
tions including crucial mutations in VP24 enable Ebola virus adaptation to new hosts. Since Reston 
virus, the only non-human pathogenic Ebolavirus species circulates in pigs in Asia, this raises concerns 
that few mutations may result in novel human pathogenic Ebolaviruses. 
Contact:	m.n.wass@kent.ac.uk, m.michaelis@kent.ac.uk j.s.rossman@kent.ac.uk   
Supplementary information:	Supplementary data are	available	at	Bioinformatics	online. 
 
 
1! Introduction  
The recent Ebola virus outbreak in West Africa was the first outbreak 
of a member of the Ebolavirus family that reached epidemic size in 
humans (La Vega et al., 2015). It resulted in more than 11,000 reported 
deaths but this is likely to be an underestimate (Meltzer et al., 2014).  
 There are currently five known members of the Ebolavirus 
family. They are: Ebola virus (formerly Zaire virus), Sudan virus, Bun-
dibugyo virus, Tai forest virus and Reston virus. Four of them are path-
ogenic in humans. The exception is Reston virus, which is not patho-
genic in humans.  Reston outbreaks in nonhuman primates have oc-
curred in Reston, USA (1989), Sienna, Italy (1992) and Texas (1996) 
but have not caused disease in humans despite individuals showing IgG 
antibodies for Reston virus (Miranda and Miranda 2011).  
Ebolavirus pathogenesis is caused by a combination of direct cy-
topathogenic effects and the deregulation of the immune response re-
sulting in massive inflammation ('cytokine storm'). A number of Ebo-
lavirus proteins have been associated with virus pathogenicity. The vi-
ral spike protein GP mediates virus entry into host cells. GP and the 
matrix protein VP40 have been implicated in causing tissue damage. 
Shed GP (variants) may contribute to the massive cytokine/ chemokine 
induction. VP35 and VP24 interfere with interferon signaling (Falasca 
et al., 2015).  
Due to the insusceptibility of rodents to Ebola virus infection and 
disease, rodent models of Ebola virus disease need to be established by 
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virus adaptation via serial passaging (Willyard, 2014). A number of 
studies have reported on the genetic changes associated with Ebola vi-
rus strain adaptation to mice, guinea pigs, and hamsters (Ebihara et al., 
2006; Dowall et al., 2014; Cross et al., 2015; Volchkov et al., 2000). 
Here, we applied an in silico approach to identify structural elements 
that are most relevant to the development of Ebola virus pathogenicity 
in a new host. 
2! Results 
Our analysis focusses on three studies that adapted Ebola viruses to 
guinea pigs (Dowall et al., 2014; Cross et al., 2015; Volchkov et al., 
2000) and one that adapted Ebola virus to mice (Ebihara et al., 2006). 
Three studies sequenced the virus once it had become pathogenic 
(Cross et al., 2015; Volchkov et al., 2000; Ebihara et al., 2006). Dowall 
et al., (2014) sequenced the virus after each passage. Methods are de-
tailed in the supplementary material. 
3.1! Mutations that are not retained during passaging  
24 of the 42 mutations that occurred during the passaging process but 
reverted to wild type in later passages (Dowall et al., 2014) could be 
mapped onto protein structures. Many of these mutations are likely to 
be destabilizing to Ebolavirus proteins (Figure 1A,B, Tables S2,S3). 
Mutations that are not retained tend to have lower BLOSUM substitu-
tion scores (indicating that such amino acid substitutions do not occur 
frequently during evolution) than the adaptation mutations (Fig 1A). 
Additionally, four of the non-retained mutations are predicted by 
mCSM (Pires et al., 2014) to be highly destabilizing (DDG < -2.5 
kcal/mol) compared to one adaptation mutation (Fig 1C, Tables S2,S4). 
All non-retained mutations occur at positions that are completely con-
served in the different Ebolavirus species (Fig 1D, Fig S5). Only two 
of the 42 (8%) non-retained adaptation-associated changes have been 
observed in Ebolaviruses, whereas 9 of the 35 (27%) retained changes 
have been observed in existing Ebolavirus genomes. This further sug-
gests that the non-retained mutations are deleterious, whereas muta-
tions that are retained may have little effect or modulate function as 
they occur in variable positions.   
In NP, both W191R and V323D are predicted to be highly desta-
bilizing to the protein (DDG of -2.973 and -3.339 kcal/mol respec-
tively). Mutation of W191 to arginine would introduce a charged resi-
due in the interior of the protein in a hydrophobic region (Figure 1E). 
This may also alter the hydrogen bond that W191 forms with E61, alt-
hough arginine retains functional groups to hydrogen bond with E61. 
Similarly, V323D introduces a charged residue in a buried region that 
is largely hydrophobic apart from H327 and E351, which form a hydro-
gen bond (Figure 1F). V323D introduces further negative charge and a 
hydrogen bond acceptor into this region, which is likely to alter the pro-
tein conformation (Figure 1F). 
In VP40, M259R introduces a larger, charged side chain, in a 
region that is surrounded largely by hydrophobic residues. Arginine at 
residue 259 could form hydrogen bonds with N257 and potentially 
other adjacent sidechains. Therefore, M259R may substantially alter 
VP40 structure. 
Temporary changes in VP30, L214P and Q248R, are also likely 
to affect VP30 structure and function (Figure 1G). L214 is buried and 
located in the last turn of an alpha helix. Mutation to proline is likely to 
shorten the helix resulting in conformational change. Q248R is in the 
VP30 homodimer interface site (Figure 1G). The backbones of adjacent 
residues L247 and L249 form hydrogen bonds with the other subunit 
(Hartlieb et al., 2007) (Figure 1G). Although Q248R is a conservative 
substitution, the increase in charge and size of the amino acid in prox-
imity to the interface may affect VP30 dimer stability. 
3.2! Overview of the adaptation-associated mutations.  
33 unique protein coding mutations were identified in the rodent-
adapted Ebola virus genomes. Mutations in GP, NP, and VP24 were 
observed in each of the separate studies (Table 1). Only in some studies, 
were mutations in L (three studies) or VP35 (two studies) observed. 
Only mutations that were not retained occurred in the remaining pro-
teins, VP30 and VP40 (Dowall et al., 2014). 
Two mutations were observed in multiple studies. The GP I554T 
mutation was observed in both the Ebihara et al.(2006) and Cross et al., 
(2015) studies, while VP24 L26F was observed in the Dowall et al., 
(2014) and Cross et al., (2015) studies. Reverse genetics studies have 
associated VP24 L26F with increased virulence in rodents (Mateo et 
al., 2011). 22 of the 33 unique mutations were mapped onto protein 
structures or models. While there is a structure or model available for 
all of the Ebola virus proteins, for some of them the full structure is not 
available. For example, the N-terminal oligomerization domains of 
VP30 and VP35 are not solved while their globular domains have been. 
For L only the N-terminal domain could be modelled.  Here we consider 
the mutations in GP, NP and VP24, all other mutations are analyzed in 
supplementary material (see Supplementary results and Figures S1-S5). 
Table 1.  Mutations identified in Ebola virus rodent adaptation exper-
iments 
Protein Ebihara Dowall Volchkov-1 Volchkov-2 Cross Total 
NP 1 1 1 N/A 2 5 
GP 3 2 1 N/A 1 7* 
L 1 11 1 N/A 0 13 
VP24 1 1 3 1 2 8* 
VP30 0 0 0 N/A 0 0 
VP35 1 1 0 N/A 0 2 
VP40 0 0 0 N/A 0 0 
Total 7 16 6 1¤ 5 35 
*VP24 L26F and GP I554T were present in two studies so total number 
of unique mutations is 7 for VP24 and 6 for GP. Two different adapta-
tion experiments were performed in Volchkov et al., and these are listed 
separately in the table. ¤data is only available for VP24 mutations in 
Volchkov-2. 
3.3! Effects of mutations in the Glycoprotein (GP) 
GP mediates host cell entry (Groseth et al., 2012). GP binding to the 
endosomal membrane protein NPC1 appears to be required for mem-
brane fusion, but the exact mechanisms remain only partially under-
stood (Miller et al., 2012). Moreover, GP is heavily glycosylated (Len-
nemann et al., 2014; 2015), which further aggravates the interpretation 
of the functional consequences of mutations. Across the four studies six 
different mutations were observed in GP (Table 1). The number of mu-
tations per study range from one (Cross Ð I554T and Volchkov) to three 
(Ebihara et al.), while two mutations were identified in Dowall study 
(Table S4). 
Four of the six mutations were mapped onto the GP protein struc-
ture (Fig S1, Tables S4, S5). There is no clustering of the mutations, 
with each of them being present in a different region of the protein. S65 
Fig. 1. Mutations not retained during pas-
saging. A) Bar chart showing BLOSUM62 sub-
stitution scores for the adaptation mutations 
(red) and those that are not retained (blue).B) 
Box plot of predicted change in protein stability 
by mCSM for mutations retained at end of pas-
saging (red) and not retained (blue). C) Conser-
vation score for mutated positions D) Conser-
vation information for retained and non-re-
tained mutations.Ð EBOV indicates the Ebola 
virus species. E) Mutation W191R (cyan) in NP 
is observed during passaging and is located in a 
buried region. F) Mutation V323D (cyan) in 
NP, is located close to H327 and E351 (blue; 
which form a hydrogen bond Ð black dashed 
line). G) Mutations L214 and Q248R (red) in 
VP30 are not retained during passaging. Zoom 
in region shows hydrogen bonding (cyan) 
around Q248 in the VP30 homodimer interface. 
 
is a buried residue in the N terminal receptor binding domain. S65P 
introduces proline into the middle of a beta sheet. This is likely to al-
ter/disrupt the beta sheet and will result in the loss of a hydrogen bond 
with E100 (Fig S1) resulting in a conformational change within GP. 
D49N is located at the edge of the interface between GP1 and GP2 (Fig 
S1). The D49 side chain is not present in the crystal structure suggesting 
that it is flexible. It could form a hydrogen bond with N595. The D49N 
mutation would reduce the charge, but asparagine would still enable the 
hydrogen bond to be formed.  S246P is located on a surface loop near 
the area that binds the host cell membrane. I544T was observed in two 
independent studies (Table S4). It is not clear how these changes would 
modulate GP function. 246 and 544 are variable positions. P246 is con-
served in Bundibugyo viruses, T544 in Reston viruses, (Fig S4). There-
fore, changes at these positions may be tolerable. S65 and D49, how-
ever, are conserved among all Ebolavirus species (Fig. S4). Hence, 
changes in these conserved regions may contribute to Ebola virus ad-
aptation to rodents. 
3.4! Effects of mutations in the nucleoprotein (NP) 
NP binds to VP30 and VP35 to form with L the viral replication ma-
chinery (Hartlieb et al., 2007; Groseth et al., 2012). NP also inhibits the 
cellular detection of viral RNA and in turn the cellular innate immune 
response and the destruction of viral RNA by ribonucleases (Fields et 
al., 2013). In three of the four studies a single mutation was present in 
NP, while two mutations were identified in the Dowall study. Three of 
the five mutations in NP could be mapped onto the protein structure 
(Figure S2, Tables S4,S6). Adjacent residues S647 and F648 (muta-
tions: S647Y and F648L) in the C terminal domain were mutated in 
separate studies and the effect of these mutations, if any was not clear 
(See supplementary material). Additionally, leucine is present at resi-
due 648 in Sudan and Reston viruses and position 647 is variable 
among the Ebolavirus species (Fig S4) indicating that these positions 
tolerate changes. Mutation S72G is in a highly conserved position and 
S72 forms a hydrogen bond with the backbone of P42, which is lost on 
mutation to glycine (Fig S2) but the consequence of this is not obvious. 
Hence, clear evidence that the NP mutations may be crucial for Ebola 
virus adaptation to rodents is lacking. 
3.5!  Multiple mutations in VP24 are likely to be asso-
ciated with Ebola virus pathogenicity 
VP24 is involved in the formation of the viral nucleocapsid, the regu-
lation of virus replication, and prevention of interferon signaling 
(Mateo et al., 2011; Feldmann and Geisbert, 2011; Watt et al., 2014; 
Reid et al., 2006). VP24 binds to STAT1 and the karyopherins α1 
(KPNA1), α5, (KPNA5), and α6 (KPNA6) (Xu et al., 2014). This bind-
ing prevents nuclear accumulation of phosphorylated STAT1 and in-
hibits interferon signaling. 
The number of mutations present in VP24 for each separate 
study ranges from one to three, with one mutation identified by Dowall, 
Ebihara and second the second Volchkov experiment, two by Cross and 
three by Volchkov (Table S4). Structural analysis using the complex of 
VP24 with human KPNA5 provided insight into the likely effects of six 
of the seven VP24 mutations found in rodent-adapted Ebola virus 
strains (Table S8). Three mutated residues (H186Y, T187I, K142E) are 
present in or adjacent to the interface site with human KPNA5 (Fig. 2) 
These mutations were identified in three independent experiments (two 
in Volchkov et al and one in Cross et al., Table S4). Wild type H186 
forms a hydrogen bond in the interface with residue T434 in human 
KPNA5 (Fig 2B). The hydroxyl group in the mutated tyrosine would 
still be able to form a hydrogen bond with KPNA5 T434 and may ena-
ble its interaction with rodent karyopherins. Tyrosine is present at po-
sition 186 in Sudan viruses (Fig S4) suggesting that this change is not 
deleterious. T187I removes intramolecular hydrogen bonds with the 
backbone of residues H186 and E203 (Fig 2C). This is likely to increase 
flexibility in this area, which may allow for binding to additional or 
different targets. K142E is adjacent to the human KPNA5 interface site 
and mutations in K142 have been shown to modulate effects on inter-
feron signaling (Ilinykh et al., 2015). This mutation reverses the charge 
of the side chain and could result in local conformational changes. 
Moreover, K142 is conserved among all Ebolavirus species (Figure 
S4), which suggests that changes at this position are likely to have func-
tional consequences. Hence, it is likely that these mutations enable or 
alter the interaction of VP24 with rodent karyopherins. 
The other three mutations (L26F, T50I and L147P) all have an 
effect on the structure of VP24. Both L26F and L147P are close in space 
to K142E (Fig 2A), L26F was observed in two studies (Dowall and 
Cross) while K142E was observed by Volchkov et al. mCSM predicted 
L26F to have the most destabilizing effect on VP24 (Table S4). L26 is 
located at the end of an alpha helix and is packed against two other 
alpha helices, resulting in the side chain being largely buried (Fig. 2D). 
Given the tight packing, mutation to a larger sidechain requires confor-
mational change to accommodate the increased size, although there is 
no indication of how this would affect VP24 function. However, given  
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Fig. 2. Mutations in VP24 during adaptation to rodents. 
A) VP24 (grey) in complex with karyopherin 5 (PDB code: 
4U2X), adaptation mutations are coloured red and shown in 
stick format. B) VP24 H186 forms a hydrogen bond with 
KPNA5 T434. C) H186 forms intramolecular hydrogen bonds 
(black dashed lines) with the backbones of H186 and E203. 
D) Residue L26 is buried so mutation L26F may affect the 
conformation of the protein. E). Adaptation mutation T50I 
will result in loss of hydrogen bonding to the backbones of 
Q36 and K52. 
 
 
that this mutation is conserved among the Ebolavirus species, was ob-
served in two independent adaptation experiments (Dowall et al., 2014; 
Cross et al., 2015) and also in reverse genetics studies (Mateo et al., 
2011), it is likely that it has a role in the adaptation to rodent hosts.  
T50I and L147P both occur at positions that vary. T50I removes 
intramolecular hydrogen bonds with the VP24 backbone residues Q36 
and K52 (Fig 2E), which is likely to increase flexibility and, hence, the 
potential for interaction with additional binding partners. L147P is lo-
cated towards the end of an alpha helix. Mutation to proline is likely to 
break the helix, leading to conformational change. Taken together, the 
evidence from our structural analysis, the pre-existing knowledge about 
the VP24 structure and function, and the consistency of VP24 mutations 
in rodent-adapted Ebola virus strains suggest that VP24 mutations are 
necessary to facilitate the interaction with STAT1 and/or the karyopher-
ins and in turn inhibition of interferon signaling in a novel host. 
 
Without the complex of VP24 bound to a guinea pig or mouse 
karyopherin we used mCSM to predict the effect of each of the adapta-
tion mutations on the affinity of VP24 with human KPNA5. The muta-
tions near the interface (K142E, L147P, H186Y and T187I) are pre-
dicted to have a destabilizing effect of between 1-1.5 kcal/mol on the 
affinity of the complex, while the other mutations are all predicted to 
have a destabilizing effect on the complex but with a smaller DDG (Ta-
ble 2). These results suggest that the adaptation mutations, particularly 
those close to the interface, are likely to have an effect on the binding 
of VP24 to rodent karyopherins, however the proposed effect would be 
to increase the affinity rather than reducing it. 
 
3!   Discussion 
Our analysis suggests that only very few mutations are necessary for 
Ebola viruses to become pathogenic in a novel host. The different ro-
dent adaptation experiments resulted in 5,6,7 or 16 mutations (Table 1 
and Table S4). Only mutations in VP24, GP and NP were observed in 













detected across these three genes, representing an upper bound on the 
minimum number of coding mutations that enable Ebolaviruses to 
cause disease in a novel, previously non-susceptible host. 
While GP and NP are mutated in each study and may have a role 
in adaptation, there is no clear evidence that mutations in them are crit-
ical for Ebola virus adaptation to a new host. GP and NP have (together 
with L) the greatest variability in their sequences (Jun et al., 2015) and 
some of the mutations are in variable positions. Therefore, variation in 
these sequences may not be surprising and may not necessarily reflect 
Ebola virus adaptation to a new host. Moreover, GP is highly glycosyl-
ated, which makes it difficult to predict whether (and if yes, how) the 
GP mutations may modulate virus tropism and pathogenicity. Notably, 
reverse genetics experiments indicated that GP contributes to human   
pathogenicity but is insufficient to establish virulence on its own (Gro-
seth et al., 2012). Hence, a substantial number of changes in the se-
quence of GP may be tolerated without losing virulence. 
 
Table 2.  Predicted effect of adaptation mutations in VP24 on protein 












L26F -1.656  destabilizing -0.644  destabilizing 
F29V -1.342  destabilizing -0.337  destabilizing 
A43P 0.55  stabilizing -0.844  destabilizing 
T50I 0.109  stabilizing -0.258  destabilizing 
K142E -1.258 destabilizing -0.995 destabilizing 
L147P -0.636  destabiliszing -1.102  destabilizing 
T187I  -1.157  destabilizing -1.454  destabilizing 
H186Y 0.589  stabilizing -1.311  destabilizing 
K218R -0.759  destabilizing -0.535  destabilizing 
 
Ebola virus adaptation to novel species 
In contrast to GP and NP, there is strong evidence that mutation 
of VP24 is vital for Ebola virus adaptation to a novel host. The VP24 
mutations H186Y, T187I and K142E occur in a region that is critical 
for karyopherin binding and the modulation of the host cell interferon 
response. Hence, these changes seem to be required to inhibit the inter-
feron response in rodents. This agrees with evidence suggesting that 
VP24 may be a determinant of species-specific pathogenicity between 
different Ebolaviruses (Zhang et al., 2012). Conserved differences in 
VP24 residues located in the VP24-karyopherin interface site (similarly 
to the adaptation mutations) that differ between Reston viruses, the only 
Ebolaviruses that are not pathogenic in humans, and the other Ebo-
laviruses have been proposed to critically contribute to the lack of hu-
man pathogenicity of Reston viruses (Pappalardo et al., 2016).  
In conclusion fewer than five mutations are required for Ebo-
lavirus adaptation to a new species. The potential for Ebolaviruses to 
adapt to novel host species is of relevance for two reasons. Firstly, cir-
culation in (domestic) species may increase the exposure of humans to 
Ebolaviruses. Reston viruses circulate in pigs and can be transmitted 
from pigs to humans (possibly by air) (Weingartl et al., 2013; Barrette 
et al., 2009; Marsh et al., 2011; Osterholm et al., 2015; Atherstone et 
al., 2015; Pan et al., 2014; Olson et al., 2012; M. E. G. Miranda and N. 
L. J. Miranda, 2011). Hence, human pathogenic Reston viruses may 
emerge. Secondly, Ebolavirus adaptation to new species (including do-
mestic species like pigs and dogs (Weingartl et al., 2013; Barrette et al., 
2009; Marsh et al., 2011; Osterholm et al., 2015; Atherstone et al., 
2015; Pan et al., 2014; Olson et al., 2012; M. E. G. Miranda and N. L. 
J. Miranda, 2011) may result in greater virus diversity and, in turn, re-
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